



MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

Limited Review Report on the Standalone Unaudited Quarterly Financial Results of the Company
Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements)
Regulations, 2015, as amended

Review Report to
The Board of Directors
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Gufic Biosciences Limited** (the "Company") for the quarter ended and six months ended 30 September 2023 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)



Piyush Agarwal
Partner

Membership No. 135505

Place: Mumbai
Dated: 09/11/2023
UDIN: **23135505B6XCWW1856**



Limited Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Gufic Biosciences Limited

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Gufic Biosciences Limited** and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter and half year ended 30 September 2023 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4) We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/20 19 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
- 5) The Statement includes the result of the entities:

Name of the Entity	Relationship
Gufic UK Limited	Subsidiary





MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

- 6) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Dated: 09/11/2023
UDIN: 23135505BGRCLWX3583



For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)

Piyush Agarwal
Partner
Membership No. 135505

GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

Unaudited Standalone and Consolidated Statement of Financial Results for the Quarter and Half Year Ended September 30, 2023

1]	Sr. No.	Particulars	Standalone						Consolidated	
			Quarter Ended			Half Year Ended		Year ended	Quarter Ended	Half Year Ended
			30-Sep-23	30-Jun-23	30-Sep-22	30-Sep-23	30-Sep-22	31-Mar-23	30-Sep-23	30-Sep-23
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited
	1	Income								
	a	Revenue from operations	21,487.41	19,502.02	17,483.53	40,989.43	34,011.16	69,062.08	21,487.41	40,989.43
	b	Other income	33.44	53.78	81.84	87.22	119.31	257.39	33.44	87.22
		Total Income	21,520.85	19,555.80	17,565.37	41,076.65	34,130.47	69,319.47	21,520.85	41,076.65
	2	Expenses								
	a	Cost of materials consumed	9,528.83	8,038.31	10,045.35	17,567.14	16,356.73	33,936.27	9,528.83	17,567.14
	b	Purchase of stock-in-trade	1,565.94	1,606.24	631.85	3,172.18	1,308.90	2,584.38	1,565.94	3,172.18
	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(184.30)	39.44	(2,138.76)	(144.86)	(1,374.03)	(3,338.61)	(184.30)	(144.86)
	d	Employee benefits expense	2,678.18	2,337.30	2,012.53	5,015.48	4,155.26	8,673.18	2,678.18	5,015.48
	e	Finance cost	446.11	407.27	160.64	853.38	251.47	822.33	446.11	853.38
	f	Depreciation and amortisation expense	429.71	423.63	456.43	853.34	892.93	2,228.10	429.71	853.34
	g	Other expenses	3,961.83	3,898.70	3,671.31	7,860.53	6,985.16	13,741.73	3,961.83	7,860.53
		Total Expenses	18,426.30	16,750.89	14,839.35	35,177.19	28,576.42	58,647.38	18,426.30	35,177.19
	3	Total Profit before exceptional items and tax (1-2)	3,094.55	2,804.91	2,726.02	5,899.46	5,554.05	10,672.09	3,094.55	5,899.46
	4	Exceptional items	-	-	-	-	-	-	-	-
	5	Total Profit Before Tax	3,094.55	2,804.91	2,726.02	5,899.46	5,554.05	10,672.09	3,094.55	5,899.46
	6	Tax expense								
		Current tax	740.00	650.00	770.00	1,390.00	1,506.00	2,821.00	740.00	1,390.00
		Deferred tax	236.31	92.62	(65.13)	328.93	(78.25)	(119.39)	236.31	328.93
		Short/(Excess) tax provision of earlier years	(202.72)	-	-	(202.72)	-	-	(202.72)	(202.72)
		Total Tax Expenses	773.59	742.62	704.87	1,516.21	1,427.75	2,701.61	773.59	1,516.21
	7	Net Profit for the period from continuing operations	2,320.96	2,062.29	2,021.15	4,383.25	4,126.30	7,970.48	2,320.96	4,383.25
	8	Total Profit for period	2,320.96	2,062.29	2,021.15	4,383.25	4,126.30	7,970.48	2,320.96	4,383.25
	9	Other Comprehensive Income (OCI)								
		Items that will not be reclassified to Profit or Loss	-	-	-	-	-	(0.71)	-	-
		Less: Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	0.18	-	-
		Other Comprehensive Income / Loss (net of taxes)	-	-	-	-	-	(0.53)	-	-
	10	Total Comprehensive Income	2,320.96	2,062.29	2,021.15	4,383.25	4,126.30	7,969.95	2,320.96	4,383.25
	11	Other Equity Reserves						33,811.37		
	12	Details of Equity Share Capital								
		Paid-up equity share capital	969.45	969.45	969.45	969.45	969.45	969.45	969.45	969.45
		Face value of equity share capital (Rs.)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
	13	Earning per equity share								
	i	Basic earnings per share from continuing and discontinued operations	2.39	2.13	2.09	4.52	4.26	8.22	2.39	4.52
	ii	Diluted earnings per share from continuing and discontinued operations	2.39	2.13	2.09	4.52	4.26	8.22	2.39	4.52

Opemml



only for identification purpose.



GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069 (CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs.in Lakhs)

Unaudited Standalone and Consolidated Statement of Assets and Liabilities as at September 30, 2023

2]	Particulars	Standalone		Consolidated
		As at 30-Sep-23	As at 31-Mar-23	As at 30-Sep-23
		(Unaudited)	(Audited)	(Unaudited)
	ASSETS			
	Non-Current Assets			
	Property, plant and equipment	13,615.04	12,684.07	13,615.04
	Intangible assets	54.96	67.88	54.96
	Capital work-in-progress	25,764.32	16,958.86	25,764.32
	Right of use assets	2,847.10	3,204.95	2,847.10
	Financial Assets			
	i. Investments	79.47	78.43	78.43
	ii. Loans	53.56	34.08	53.56
	iii. Other financial assets	897.01	809.07	897.01
	Deferred tax assets (net)	-	96.64	-
	Other non-current assets	2,486.56	5,771.11	2,486.56
	Total Non-Current Assets	45,798.02	39,705.09	45,796.98
	Current Assets			
	Inventories	19,221.24	18,345.75	19,221.24
	Financial Assets			
	i. Investments	-	-	-
	ii. Trade receivables	26,500.73	20,546.57	26,500.73
	iii. Cash and cash equivalent	431.60	2,860.19	432.64
	iv. Bank balances	1,199.10	1,808.48	1,199.10
	v. Loans	20.15	20.44	20.15
	Other current assets	3,767.87	2,829.43	3,767.87
	Total Current Assets	51,140.69	46,410.86	51,141.73
	TOTAL ASSETS	96,938.71	86,115.95	96,938.71
	EQUITY AND LIABILITIES			
	Equity			
	Equity share capital	969.45	969.45	969.45
	Other equity	38,097.68	33,811.37	38,097.68
	Total Equity	39,067.13	34,780.82	39,067.13
	Liabilities			
	Non-Current Liabilities			
	Financial Liabilities			
	i. Borrowings	16,721.54	19,067.93	16,721.54
	ii. Other Financial Liabilities	496.01	496.01	496.01
	iii. Lease liability	1,267.03	1,620.99	1,267.03
	Provisions	1,338.47	1,329.45	1,338.47
	Deferred tax liabilities (net)	232.28	-	232.28
	Total Non- Current Liabilities	20,055.33	22,514.38	20,055.33
	Current Liabilities			
	Financial Liabilities			
	i. Borrowings	17,194.12	12,072.78	17,194.12
	ii. Trade payables			
	Total outstanding dues of micro enterprises and small enterprises	873.43	981.03	873.43
	Total outstanding dues of other than micro enterprises and small enterprises	14,402.55	12,045.43	14,402.55
	iii. Other financial liabilities	1,073.16	1,076.92	1,073.16
	iv. Lease liability	690.87	657.58	690.87
	Provisions	414.10	424.12	414.10
	Other current liabilities	2,525.18	1,250.48	2,525.18
	Current tax liabilities (net)	642.84	312.41	642.84
	Total Current Liabilities	37,816.25	28,820.75	37,816.25
	Total Liabilities	57,871.58	51,335.13	57,871.58
	TOTAL EQUITY AND LIABILITIES	96,938.71	86,115.95	96,938.71

only for identification
purpose



Demmi

GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069 (CIN- L24100MH1984PLC033519)
Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs)

Unaudited Standalone and Consolidated Statement of cash flows for the Half-year ended September 30, 2023

3]	Particulars	Standalone		Consolidated
		Half Year Ended 30-Sep-23	Half Year Ended 30-Sep-22	Half Year Ended 30-Sep-23
		(Unaudited)	(Unaudited)	(Unaudited)
	A. Cash flows from operating activities			
	Profit for the year	4,383.25	4,126.30	4,383.25
	Adjustments for:			
	Income tax expense recognised in profit or loss	1,516.21	1,427.75	1,516.21
	Depreciation	853.34	892.93	853.34
	Dividend	-	(0.05)	-
	Interest income on fixed deposits with banks	(42.13)	(33.36)	(42.13)
	Interest income on financial assets carried at amortised cost	(26.72)	(28.64)	(26.72)
	Interest costs on financial liabilities measured at amortised cost	853.38	251.47	853.38
	Non current security deposits at amortised cost	29.27	23.36	29.27
	Profit on sale of fixed asset	(10.55)	-	(10.55)
	Loss on sale of fixed asset	82.18	-	82.18
	Sundry credit balances written back	3.39	(11.03)	3.39
	Operating profit before movements in the working capital	7,641.63	6,648.73	7,641.63
	Movements in working capital:			
	(Increase)/decrease in trade and other receivables	(6,978.11)	(4,000.21)	(6,978.11)
	(Increase)/decrease in inventories	(875.49)	(5,261.14)	(875.49)
	Increase/ (Decrease) in trade and other payables	2,308.54	429.72	2,308.54
		(5,545.06)	(8,831.62)	(5,545.06)
	Cash generated from / (used in) operations	2,096.57	(2,182.90)	2,096.57
	Income taxes paid	(867.02)	(832.91)	(867.02)
	Net cash generated from / (used in) operating activities (A)	1,229.55	(3,015.81)	1,229.55
	B. Cash flows from investing activities			
	Purchase of property, plant and equipments including capital advances	(5,926.54)	(6,708.29)	(5,926.54)
	Purchase of Investment in Equity Shares of Subsidiary	(1.04)	-	-
	Sale of property, plant and equipments	11.92	-	11.92
	Other dividend received	-	0.05	-
	Investment in equity	-	(77.68)	-
	Balance in earmarked accounts	609.39	(201.24)	609.39
	Interest income on fixed deposits with banks	42.11	52.97	42.11
	Net cash used in investing activities (B)	(5,264.15)	(6,934.19)	(5,263.11)
	C. Cash flows from financing activities			
	Proceeds / (Repayment) from current borrowings	5,121.34	5,822.66	5,121.34
	Proceeds / (Repayment) from non current borrowings	(2,346.39)	6,437.64	(2,346.39)
	Processing fees paid	(48.50)	-	(48.50)
	Payment on lease liabilities	(320.67)	(153.67)	(320.67)
	Payment for Interest lease liability	(109.97)	(14.33)	(109.97)
	Dividends paid on equity shares	-	(96.76)	-
	Interest paid	(689.79)	(257.60)	(689.79)
	Net cash generated from financing activities (C)	1,606.02	11,737.94	1,606.02
	Net increase in cash and cash equivalents (A + B + C)	(2,428.59)	1,787.94	(2,427.55)
	Cash and cash equivalents at the beginning of the year	2,860.19	1,160.80	2,860.19
	Cash and cash equivalents at the end of the period	431.60	2,948.74	432.64

only for identification
purpose



[Signature]



Notes:

1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder.
2. The above results for the quarter ended September 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 09, 2023. The Statutory Auditors have carried out limited review of the results for quarter and half-year ended September 30, 2023.
3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
4. The Company has incorporated Gufic UK Limited ("GUL") in the United Kingdom on March 15, 2022, and Gufic Ireland Limited ("GIL") in Ireland on March 02, 2023, with the intention of making both companies its Wholly Owned Subsidiaries. With respect to GIL, as of September 30, 2023, neither investment had been made in GIL nor GIL has begun its business operations. Consequently, there was no need to consolidate the accounts of GIL with the Company. Whereas with respect to GUL, the Company on September 13, 2023, invested in GUL by subscribing to its shares, however, GUL has not initiated its business operations by September 30, 2023. Therefore, the consolidated financial results for the quarter and half-year ending on September 30, 2023, have been prepared by the Company considering the financials of GUL.
5. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED



PANKAJ J. GANDHI
WHOLE TIME DIRECTOR
DIN: 00001858



PLACE : MUMBAI
DATE : 09/11/2023

